Trial Profile
The efficacy of Eylea to treat proliferative diabetic retinopathy/preproliferative diabetic retinopathy in patients with diabetic macular edema
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy
- Focus Therapeutic Use
- 22 Dec 2018 Status changed from recruiting to discontinued.
- 14 Jun 2018 Status changed from not yet recruiting to recruiting.
- 14 Dec 2016 Planned number of patients changed from 40 to 50.